title: Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice.
abstract: Fabry disease (FD) is an X-linked disorder of glycosphingolipid catabolism resulting in the accumulation of glycolipids including globotriaosylceramide in cells of various tissues resulting in end-organ manifestations. Initially, FD is typically characterized by angiokeratoma and recurrent episodes of neuropathic pain in the extremities occurring during childhood or adolescence. Most affected patients also exhibit a decreased ability to sweat. Later in life, FD results in left ventricular hypertrophy, proteinuria, renal failure and stroke. These later disease manifestations are non-specific and also common in diabetes, hypertension and atheromatosis and thus for most practitioners do not point into the direction of FD. As a consequence, FD is under-diagnosed and screening of high-risk groups is important for case finding, as is a thorough pedigree analysis of affected patients. In the nephrology clinic, we suggest to screen patients for FD when there is unexplained chronic kidney disease in males younger than 50 years and females of any age. In men, this can be performed by measuring α-galactosidase A activity in plasma, white blood cells or dried blood spots. In women, mutation analysis is necessary, as enzyme measurement alone could miss over one-third of female Fabry patients. A multidisciplinary team should closely monitor all known Fabry patients, with the nephrologist screening kidney impairment (glomerular filtration rate and proteinuria) on a regular basis. Transplanted Fabry patients have a higher mortality than the regular transplant population, but have acceptable outcomes, compared with Fabry patients remaining on dialysis. It is unclear whether enzyme replacement therapy (ERT) prevents deterioration of kidney function. In view of the lack of compelling evidence for ERT, and the low likelihood that a sufficiently powered randomized controlled trial on this topic will be performed, data of all patients with FD should be collected in a central registry.
authors.affiliation: Department of Internal Medicine,Regional Hospital Jan Yperman, Ypres, Belgium. guidelines@era-edta.org
authors.forename: Wim
authors.initials: W
authors.lastname: Terryn
authors.forename: Pierre
authors.initials: P
authors.lastname: Cochat
authors.forename: Roseline
authors.initials: R
authors.lastname: Froissart
authors.forename: Alberto
authors.initials: A
authors.lastname: Ortiz
authors.forename: Yves
authors.initials: Y
authors.lastname: Pirson
authors.forename: Bruce
authors.initials: B
authors.lastname: Poppe
authors.forename: Andreas
authors.initials: A
authors.lastname: Serra
authors.forename: Wim
authors.initials: W
authors.lastname: Van Biesen
authors.forename: Raymond
authors.initials: R
authors.lastname: Vanholder
authors.forename: Christoph
authors.initials: C
authors.lastname: Wanner
mesh_terms: D005060:Europe; D000795:Fabry Disease / Q000175:diagnosis* / Q000628:therapy*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000175:diagnosis* / Q000628:therapy*; D008297:Male; D008403:Mass Screening; D017410:Practice Guidelines as Topic